Long-term Erythropoietin expression in rodents and non-human primates following intramuscular injection of a replication-defective adenoviral vector

Human Gene Therapy

Volumn 8, Issue 15, 1997, Pages 1797-1806

  Svensson, Eric C ^a  

^a Departments of Preventive Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; VIRUS VECTOR;

ADENOVIRUS; ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; HEMATOCRIT; MOUSE; NONHUMAN; POLYCYTHEMIA; PRIMATE; RODENT;

ADENOVIRIDAE; ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; MURINAE; PRIMATES; RODENTIA; SIMIAE;

EID: 0030669598     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1997.8.15-1797     Document Type: Article

References (31)

1. BARR, E., and LEIDEN, J.M. (1991). Systemic delivery of recombinant proteins by genetically modified myoblasts. Science 254, 1507-1509.
2. BARR, E., CARROLL, J., KALYNYCH, A.M., TRIPATHY, S.K., KOZARSKY, K., WILSON, J.M., and LEIDEN, J.M. (1994). Efficient catheter-mediated gene transfer into the heart using replication-defective adenovirus. Gene Ther. 1, 51-58.
3. BARR, D., TUBB, J., FERGUSON, D., SCARIA, A., LIEBER, A., WILSON, C., PERKINS, J., and KAY, M.A. (1995). Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains. Gene Ther. 2, 151-155.
4. BLAU, H.M., and SPRINGER, M.L. (1995). Muscle-mediated gene therapy. N. Engl. J. Med. 333, 1554-1556.
5. BOHL, D., NAFFAKH, N., and HEARD, J.M. (1997). Long-term control of erythropoietin secretion by doxycycline in mice transplanted with engineered primary myoblasts. Nature Med. 3, 299-305.
6. BRODY, S.L., METZGER, M., DANEL, C., ROSENFELD, M.A., and CRYSTAL, R.G. (1994). Acute responses of non-human primates to airway delivery of an adenovirus vector containing the human cystic fibrosis transmembrane conductance regulator cDNA. Hum. Gene Ther. 5, 821-836.
7. DAI, Y., ROMAN, M., NAVIAUX, R.K., and VERMA, I.M. (1992). Gene therapy via primary myoblasts: long-term expression of factor IX protein following transplantation in vivo. Proc. Natl. Acad. Sci. USA 89, 10892-10895.
8. DAI, Y., SCHWARZ, E.M., GU, D., ZHANG, W.W., SARVETNICK, N., and VERMA, I.M. (1995). Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc. Natl. Acad. Sci. USA 92, 1401-1405.
9. DHAWAN, J., PAN, L.C., PAVLATH, G.K., TRAVIS, M.A., LANCTOT, A.M., and BLAU, H.M. (1991). Systemic delivery of human growth hormone by injection of genetically engineered myoblasts. Science 254, 1509-1512.
10. DHAWAN, J., RANDO, T.A., ELSON, S.L., BUJARD, H., and BLAU, H.M. (1995). Tetracycline-regulated gene expression following direct gene transfer into mouse skeletal muscle. Somat. Cell Mol. Genet. 21, 233-240.
11. ESCHBACH, J.W., EGRIE, J.C., DOWNING, M.R., BROWNE, J.K., and ADAMSON, J.W. (1987). Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N. Engl. J. Med. 316, 73-78.
12. FISCHL, M., GALPIN, J.E., LEVINE, J.D., GROOPMAN, J.E., HENRY, D.H., KENNEDY, P., MILES, S., ROBBINS, W., STARRETT, B., and ZALUSKY, R. (1990). Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N. Engl. J. Med. 322, 1488-1493.
13. HAMAMORI, Y., SAMAL, B., TIAN, J., and KEDES, L. (1995). Myoblast transfer of human erythropoietin gene in a mouse model of renal failure. J Clin. Invest. 95, 1808-1813.
14. HOSKEN, N.A., SHIBUYA, K., HEATH, A.W., MURPHY, K.A., and O'GARRA, A. (1995). The effect of antigen dose on CD4+ T helper cell phenotype development in a T cell receptor-ab-transgenic model. J. Exp. Med. 182, 1579-1584.
15. KASS, E.A., FALCK, P.E., ELFENBEIN, D.H., ALVIRA, M., BUTTRICK, P.M., and LEINWAND, L.A. (1994). The impact of developmental stage, route of administration and the immune system on adenovirus-mediated gene transfer. Gene Ther. 1, 395-402.
16. KESSLER, P.D., PODSAKOFF, G.M., CHEN, X., MCQUISTON, S.A., COLOSI, P.C., MATELIS, L.A., KURTZMAN, G.J., and BYRNE, B.J. (1996). Gene delivery to skeletal muscle results in sustained expression and systemic delivery for a therapeutic protein. Proc. Natl. Acad. Sci. USA 93, 14082-14087.
17. MASTRANGELI, A., HARVEY, B.G., YAO, J., WOLFF, G., KOVESDI, I., CRYSTAL, R.G., and FALCK-PEDERSEN, E. (1996) "Sero-switch" adenovirus-mediated in vivo gene transfer: Circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. Hum. Gene Ther. 7, 79-87.
18. NAFFAKH, N., HENRI, A., VILLEVAL, J.L., ROUYER, F.P., MOULLIER, P., BLUMENFELD, N., DANOS, O., VAINCHENKER, W., HEARD, J.M., and BEAUZARD, Y. (1995). Sustained delivery of erythropoietin in mice by genetically modified skin fibroblasts. Proc. Natl. Acad. Sci. USA 92, 3194-3198.
19. OSBORNE, W.A.R., RAMESH, N., LAU, S., CLOWES, M.M., DALE, D.C., and CLOWES, A.W. (1995). Gene therapy for long-term expression of erythropoietin in rats. Proc. Natl. Acad. Sci. USA 92, 8055-8058.
20. SARZOTTI, M., ROBBINS, D.S., and HOFFMAN, P.M. (1996). Induction of protective CTL responses in newborn mice by a murine retrovirus. Science 271, 1726-1728.
21. + T cells from allergic individuals is modulated by antigen concentration and antigen-presenting cell type. J. Exp. Med. 181, 1081-1089.
22. SVENSSON, E.C., TRIPATHY, S.K., and LEIDEN, J.M. (1996). Muscle-based gene therapy: realistic possibilities for the future. Mol. Med. Today 2, 166-172.
23. TABBARA, I.A. (1993). Erythropoietin. Biology and clinical applications. Arch. Intern. Med. 153, 298-304.
24. TRIPATHY, S.K., GOLDWASSER, E., LU, M.M., BARR, E., and LEIDEN, J.M. (1994). Stable delivery of physiologic levels of recombinant erythropoietin to the systemic circulation by intramuscular injection of replication-defective adenovirus. Proc. Natl. Acad. Sci. USA 91, 11557-11561.
25. TRIPATHY, S.K., BLACK, H.B., GOLDWASSER, E., anD LEIDEN, J.M. (1996a). Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nature Med. 2, 545-550.
26. TRIPATHY, S.K., SVENSSON, E.C., BLACK, H.B., GOLDWASSER, E., MARGALITH, M., HOBART, P.M., and LEIDEN, J.M. (1996b). Long-term expression of erythropoietin in the systemic circulation of mice after intramuscular injection of a plasmid DNA vector. Proc. Natl. Acad. Sci. USA 93, 10876-10880.
27. + CTLs in vivo. J. Immunol. 155, 2564-2570.
28. YANG, Y., NUNES, F.A., BERENCSI, K., FURTH, E.E., GONCZOL, E., and WILSON, J.M. (1994). Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. USA 91, 4407-4411.
29. + CTLs in vivo. J Immunol. 155, 2564-2570.
30. YANG, Y., JOOSS, K.U., SU, Q., ERTL, H.C., and WILSON, J.M. (1996). Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther. 3, 137-144.
31. YAO, S.N., and KURACHI, K. (1992). Expression of human factor IX in mice after injection of genetically modified myoblasts. Proc. Natl. Acad. Sci. USA 89, 3357-3361.